Table 1.
Patient characteristics at the start and end of ruxolitinib treatment (N = 86)
| Parameter | Baseline, N (%) | At treatment discontinuation, N (%) | P |
|---|---|---|---|
| Age ≥ 65 y | 45 (52) | 58 (67) | <.0001 |
| Sex (female) | 36 (42) | 36 (42) | |
| Diagnosis | |||
| Primary | 56 (65) | 56 (65) | |
| Post ET | 9 (11) | 9 (11) | |
| Post PV | 21 (24) | 21 (24) | |
| Hgb < 10 g/dL | 39 (45) | 52 (61) | .002 |
| PLT, median (range), ×109/L | 262 (13-1183) | 91 (11-922) | <.001 |
| WBC ≥ 25 × 109/L | 29 (34) | 34 (40) | .493 |
| PB blasts ≥1% | 44 (51) | 51/80 (64) | .356 |
| PS > 0 | 73 (85) | 80 (93) | .053 |
| Spleen size,* median (range), cm | 20 (0-30) | 14 (0-36) | <.001 |
| Transfusion-dependent | 25 (29) | 36/84 (43) | .001 |
| JAK2 allele burden (range), % | 79 (20-99) | 65 (6-99) | .411 |
| Cytogenetic | |||
| Diploid | 22/53 (42) | 16/53 (30) | <.0001 |
| Abnormal | 31/53 (59) | 37/53 (70) | |
| Complex karyotype† | 7/53 (13) | 13/53 (25) | .007 |
BM, bone marrow; Hgb, hemoglobin; NA, not available; PB, peripheral blood; PLT, platelets; WBC, white blood cell count.
*
Evaluable for spleen size at baseline (82/86) and evaluable at discontinuation (68/86).
†
Data reported for 50 patients with cytogenetic information at baseline and follow-up. At baseline, 39/85 patients had abnormal cytogenetics (8 of which were complex karyotype). Complex karyotype is defined as 3 or more unrelated abnormalities.